Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Globe Newswire•24/10/2026•02:30 ET
0
Key Highlights
- ➤IMA402 posts 32% cORR in PRAME-high melanoma, with 12.5-month median DOR
- ➤IMA402 reports 91% one-year overall survival in PRAME-high melanoma patients
- ➤IMA203CD8 achieves 55% cORR in gynecologic cancers at clinically relevant doses
- ➤IMA203CD8 delivers 41% cORR across 90 evaluable advanced solid-tumor patients
- ➤IMA402 development expands across melanoma, gynecologic and lung cancer indications
Expert Statements
Cedrik Britten, Chief Medical Officer at Immatics
“The data presented at ESMO further underscore the potential of IMA402 as an off-the-shelf treatment option for patients with solid cancers. This promising clinical profile reinforces our strategy as we continue to advance IMA402 across multiple cancer types and treatment lines, with combination approaches further expanding its reach”
Cedrik Britten, Chief Medical Officer at Immatics
“In addition, as the IMA203CD8 PRAME cell therapy data continue to mature, we are increasingly encouraged by its broad potential for patients with advanced PRAME-positive cancers. Together with anzu-cel, IMA402 and IMA203CD8 give us three distinct and complementary approaches to target PRAME, with the potential to reach more patients across a broad range of cancers.”
* IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile
* IMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of 91% in advanced melanoma patients with high PRAME expression
Get started
Create a free account to read the full story.